Sandoz built up its biosimilar capabilities with a new $400 million manufacturing ... resources to fit its best needs and grow the business. Sandoz is one of the largest biosimilars players ...

Novartis’ generics unit Sandoz will tell ... at an investor update in New York later today, pointing to six quarters of consecutive growth that helped sales grow to $9.1 billion last year ...

Once operational, the new facility will support a growing biosimilar medicines business at Sandoz, which currently includes eight approved products, with versions of Regeneron and Bayer’s ...